Dr. Laurie Glimcher

Laurie H. Glimcher, MD, is the former President and CEO of the Dana-Farber Cancer Institute, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. From 1991 to 2012 she served as the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School serving as Senior Physician and Rheumatologist at Brigham and Woman’s Hospital. Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.

Dr. Glimcher is a Member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Member of the National Academy of Medicine, and the former President of the American Association of Immunologists. She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, and Repare Therapeutics Scientific Advisory Boards, the Lasker Award Jury, the American Association for Cancer Research, the Association of American Cancer Institutes, and the American Society of Clinical Oncology. She is the co-founder of Quentis Therapeutics. She previously served on the Board of Directors of the Bristol Myers Squibb pharmaceutical corporation, and is currently on the Corporate Board of Directors of the GlaxoSmithKline pharmaceutical corporation and the Waters Corporation.

A trailblazer in cancer research, Dr. Glimcher is celebrated for her research discoveries in the fields of transcriptional regulation, lymphocyte differentiation, immunology, and osteobiology. As an immunologist, her primary research interests are elucidating the molecular pathways that regulate the immune system, critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, skeletal biology, and translational medicine, and has contributed more than 350 scholarly articles and papers to the medical literature.

Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed Dean of Weill Cornell Medicine in New York, and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute.

Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.

https://www.dana-farber.org/about-us/leadership/laurie-glimcher/
https://en.wikipedia.org/wiki/Laurie_Glimcher